Business Context and Reporting Period
Company: Orthofix International N.V. (Orthofix Medical Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: Orthofix is a multinational corporation designing, developing, manufacturing, and distributing medical equipment for the orthopedic market. Operations are divided into four segments: Domestic, Spinal Implants and Biologics, Breg, and International.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2009 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Net Sales | $137,546 | $266,520 |
| Gross Profit | $100,637 | $196,805 |
| Gross Margin | 73.2% | 73.8% |
| Operating Income | $13,645 | $24,145 |
| Net Income | $5,944 | $8,823 |
| Diluted EPS | $0.35 | $0.51 |
| Cash and Cash Equivalents | $5,918 | $5,918 (Balance Sheet) |
| Restricted Cash | $15,617 | $15,617 (Balance Sheet) |
| Total Debt (Current + Long-Term) | $267,323 | $267,323 (Balance Sheet) |
| Operating Cash Flow (6mo) | N/A | $16,983 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6% ($137.5M) for the quarter and 3% ($266.5M) for the six months compared to the prior year periods. Growth was driven by the Domestic and Spinal Implants segments, partially offset by a 10% decline in International sales due to foreign currency fluctuations.
- Profitability: Net income increased slightly to $5.9M for the quarter (from $5.8M) but decreased to $8.8M for the six months (from $9.4M). Operating income improved to $13.6M for the quarter.
- Expense Increases:
- R&D: Increased significantly ($8.9M for the quarter, $18.0M for six months) due to collaborative arrangements with Musculoskeletal Transplant Foundation (MTF) and Intelligent Implant Systems (IIS).
- G&A: Increased due to restructuring charges ($1.7M for the quarter, $3.0M for six months) related to consolidating Blackstone operations.
- Amortization: Decreased significantly ($1.6M for the quarter) compared to the prior year due to the impairment of definite-lived intangible assets at Blackstone in late 2008.
- Working Capital: Days sales in receivables improved to 79 days (from 83 days), and inventory turns improved to 1.6 times (from 1.2 times).
Guidance, Outlook, Risks, and Unusual Items
- Collaborative Arrangements: The Company expects to incur up to $6.7 million in expenses related to MTF and IIS agreements for the remainder of 2009.
- Restructuring: A plan to consolidate Blackstone operations is expected to be completed by the fourth quarter of 2009.
- Derivatives: An interest rate swap (notional $150M) is no longer deemed highly effective; mark-to-market adjustments are recorded in current earnings. The Company recorded an unrealized non-cash gain of $1.0M (quarter) and $1.3M (six months) on this swap.
- Legal Proceedings (Significant Risk):
- Blackstone Matters: Multiple federal grand jury subpoenas and qui tam complaints (False Claims Act) regarding physician compensation and marketing practices. The Company is seeking indemnification from an escrow fund established during the Blackstone acquisition, but former shareholders are contesting these claims. Approximately $11.5 million is recorded as an escrow receivable.
- Bone Growth Stimulators: New qui tam complaints and a HIPAA subpoena regarding the classification and marketing of bone growth stimulators (sale vs. rental) and alleged kickbacks.
- Liquidity: The Company is in compliance with financial covenants (Leverage ratio 3.60; Fixed charge ratio 1.42). Management believes current cash and credit facilities are sufficient for near-term needs.
Investor Verification Checklist
- Escrow Fund Status: Verify the likelihood of recovering the $11.5 million escrow receivable given the objections from former Blackstone shareholders.
- Legal Exposure: Assess the potential financial impact of the ongoing False Claims Act investigations and qui tam lawsuits regarding physician compensation and product marketing.
- Debt Covenants: Monitor the leverage and fixed charge ratios to ensure continued compliance with the senior secured credit facility, especially given the high debt load ($267M).
- Collaboration Costs: Confirm the actual run-rate of R&D expenses related to the MTF and IIS partnerships against the projected $6.7 million for 2009.
- International Currency Impact: Evaluate the sensitivity of future earnings to foreign exchange rates, as the strengthening US dollar negatively impacted International sales by approximately $10.6 million in the first half of 2009.